First Eagle Investment Management LLC reduced its holdings in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 50.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,268,924 shares of the company's stock after selling 1,273,924 shares during the quarter. First Eagle Investment Management LLC owned 2.51% of CryoPort worth $22,079,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in CYRX. State of Alaska Department of Revenue acquired a new stake in shares of CryoPort in the 3rd quarter worth about $40,000. State of Wyoming acquired a new position in CryoPort during the 3rd quarter valued at about $81,000. Counterpoint Mutual Funds LLC acquired a new position in CryoPort during the 3rd quarter valued at about $324,000. Highland Investment Advisors LLC bought a new stake in CryoPort during the 2nd quarter worth approximately $306,000. Finally, Diversified Trust Co increased its holdings in CryoPort by 3.4% during the 3rd quarter. Diversified Trust Co now owns 19,769 shares of the company's stock worth $344,000 after purchasing an additional 657 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at CryoPort
In other CryoPort news, Director Daniel Hancock sold 74,379 shares of the company's stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $20.21, for a total value of $1,503,199.59. Following the completion of the sale, the director owned 69,052 shares of the company's stock, valued at $1,395,540.92. This represents a 51.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark W. Sawicki sold 10,000 shares of the company's stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $19.93, for a total transaction of $199,300.00. Following the completion of the sale, the insider directly owned 92,356 shares of the company's stock, valued at $1,840,655.08. This trade represents a 9.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 9.50% of the stock is currently owned by corporate insiders.
CryoPort Stock Performance
Shares of CYRX opened at $19.74 on Wednesday. The business has a 50-day moving average of $17.60 and a 200 day moving average of $13.80. CryoPort, Inc. has a fifty-two week low of $7.61 and a fifty-two week high of $21.78. The firm has a market cap of $1.00 billion, a P/E ratio of -20.35 and a beta of 1.89.
CryoPort (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $50.22 million for the quarter, compared to analysts' expectations of $48.66 million. CryoPort had a negative return on equity of 8.28% and a negative net margin of 21.46%. As a group, research analysts predict that CryoPort, Inc. will post -0.88 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on the company. Weiss Ratings upgraded CryoPort from a "sell (d)" rating to a "hold (c-)" rating in a report on Thursday, October 8th. Roth Capital reiterated a "buy" rating and set a $21.00 price target on shares of CryoPort in a report on Friday, August 7th. Piper Sandler upgraded CryoPort to a "buy" rating in a report on Tuesday, October 13th. Guggenheim increased their price target on CryoPort from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Thursday, October 1st. Finally, BTIG Research raised their price objective on CryoPort from $25.00 to $26.00 and gave the company a "buy" rating in a research note on Tuesday, October 13th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, CryoPort currently has a consensus rating of "Moderate Buy" and a consensus target price of $21.69.
View Our Latest Analysis on CryoPort
CryoPort Profile
(
Free Report)
Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company's services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CryoPort, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CryoPort wasn't on the list.
While CryoPort currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.